GEFTIB GEFTINIB TABLETS

Get a Price/Quote

GEFTIB GEFTINIB TABLETS Specification

Indication
Treatment of locally advanced or metastatic non-small cell lung cancer with EGFR mutations

Origin of Medicine
India

Salt Composition
Gefitinib 250 mg

Dosage Form
Tablet

Pacakaging (Quantity Per Box)
30 tablets per box

Drug Type
Other Types

Ingredients
Gefitinib

Physical Form
Tablets

Function
Anticancer, EGFR inhibitor

Recommended For
Non-small cell lung cancer

Dosage
250 mg

Dosage Guidelines
As directed by the physician

Suitable For
Adults

Quantity
30 Tablets

Storage Instructions
Store below 25C in a dry place, protected from light

Packaging Type
Box

Prescription/Non Prescription
Prescription

Route of Administration
Oral

Marketed In
India and selected countries

Brand Name
GEFTIB

Warning
To be sold by retail on the prescription of an oncologist only

Therapeutic Class
Antineoplastic agents

Color
White to off-white

Shelf Life
24 Months

GEFTIB GEFTINIB TABLETS Trade Information

Packaging Details
Pack of 30 tablets

Main Domestic Market
All India

Certifications
Brand Name: GEFTIB Content: Gefitinib Strengths: 250 mg Form : Tablets Packing: Pack of 30 tablets Manufactured By: Glenmark

About GEFTIB GEFTINIB TABLETS

GEFTINIB TABLETS

Specifications:-

Brand Name: GEFTIB
Content: Gefitinib
Strengths: 250 mg
Form : Tablets
Packing: Pack of 30 tablets
Manufactured By: Glenmark

Note :- GEFTIB Is A Prescription Drug And Should Be Used Under Proper Medical Guidance And Advice. Do Not Share The Medicine With Others, Since They May Be Suffering From A Problem That Is Not Effectively Treated By This Drug.................

Targeted Therapy for Non-Small Cell Lung Cancer

GEFTIB Tablets are designed to specifically target non-small cell lung cancer in adults with EGFR mutation-positive tumors. This precision gives eligible patients an effective, well-studied therapeutic option that interferes with cancer cell growth and progression.

Safeguarded Prescribing and Distribution

Strictly distributed under prescription by oncologists, GEFTIB ensures patient safety and appropriateness of therapy. The regulated sale and packaging (30 tablets per box) support secure storage and discrete dosing to safeguard both efficacy and patient health.

Optimized for Convenience and Safety

Orally administered GEFTIB Tablets can be taken at home as advised by the physician, providing convenience without compromising treatment integrity. Safe handling and storage help preserve the medications quality and therapeutic potential over its 24-month shelf life.

FAQs of GEFTIB GEFTINIB TABLETS:

Q: How should GEFTIB Gefitinib Tablets be taken for cancer treatment?

A: GEFTIB tablets are taken orally, generally once daily, exactly as directed by your physician. Do not alter your dose or schedule without consulting your oncologist.

Q: What is the primary benefit of using GEFTIB Gefitinib Tablets?

A: This medication targets and inhibits EGFR, which can slow or stop cancer growth in adults with non-small cell lung cancer that has certain EGFR mutations.

Q: When is GEFTIB Gefitinib prescribed, and for whom is it suitable?

A: GEFTIB is prescribed for adults diagnosed with locally advanced or metastatic non-small cell lung cancer, specifically when tests confirm EGFR mutations. It should only be used under the guidance of a certified oncologist.

Q: Where should I store GEFTIB tablets to maintain their potency?

A: Store the tablets below 25C in a dry place, away from direct light and moisture, to ensure the medication remains effective during its shelf life.

Q: What steps are involved in starting treatment with GEFTIB Gefitinib?

A: An oncologist will evaluate your cancer for EGFR mutations and prescribe GEFTIB if indicated. You should undergo regular follow-ups for dose adjustments and monitoring during therapy.